The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: John Purtell - Macquarie Research - Analyst
: Luis, congrats on what you've achieved over the last 5 years and all the best going forward. Just had a couple of questions, if I could. Just starting
with Geochem there. You've referenced a sort of sequential improvement towards the end of the period, and that's really reflective of sort of market
share increase rather than the market itself.
So I suppose the question is kind of how do you assess sort of the state of the market at the moment. And obviously, you've referenced the
high-performance categories, but are there any particular call-outs in terms of commodities or end markets where you're taking that share increase?
Question: John Purtell - Macquarie Research - Analyst
: And just a second question is on Pharma. You've obviously highlighted an expectation of improvement in second half margins. What's driving
that? And presuming that relates to base Pharma, because I think on Nuvisan, you sort of said improvement in margins ex Nuvisan there, so what's
driving that improvement in Pharma margins? And you've also referenced some operational improvements there for Nuvisan. Should we expect
those to flow through in the second half such that we have a better second half than the first for Nuvisan?
Question: Peter Drew - Carter Bar Securities, Research Division - Analyst
: Malcolm, Luis, congrats on the results. And thanks very much, Luis, for all your help and guidance over the past 5 years, and all the best. Just got a
couple of questions. Just firstly, could you just provide a little bit more context on the Geochem business, sort of where it is, I guess, from a revenue
perspective, a revenue growth perspective? I mean volumes have improved, and you've also got this revenue per sample sort of feature improvement.
I'm just wondering, is the Geochem business back in revenue growth? Or is it still contracting?
Question: Peter Drew - Carter Bar Securities, Research Division - Analyst
: Yes. I guess putting the question maybe a bit more clearly is as those -- that volume decline reduced through the half, was -- and you've also got
revenue per sample growing from an uptake in the high-performing methods, I'm just wondering, was there a crossover point during the half
where it actually was producing growth versus PCP?
Question: Peter Drew - Carter Bar Securities, Research Division - Analyst
: Just moving on to the comments on improvement in second half Life Sciences margin, just to clarify, you're referencing improvement versus the
second half of fiscal '23, correct?
|
